Skip to main content

Table 3 Selected toxicity profile

From: When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan

 

With anti-angiogenesis

(n = 60)

Without anti-angiogenesis

(n = 144)

Any grade

≥ grade 3

Any grade

≥ grade 3

Hepatitis

10 (16.7%)

0 (0%)

18 (12.5%)

0 (0%)

Diarrhea

26 (43.3%)

1 (1.7%)

52 (36.1%)

1 (0.7%)

Dermatitis acneiform

35 (58.3%)

7 (11.7%)

56 (38.9%)

4 (2.8%)

Paronychia

29 (48.3%)

1 (1.7%)

60 (41.7%)

5 (3.5%)

Skin rash

6 (10%)

3 (5%)

27 (18.8%)

6 (4.2%)

Oral ulcer

8 (13.3%)

0 (0%)

33 (22.9%)

1 (0.7%)

Proteinuria

13 (21.7%)

0 (0%)

0 (0%)

0 (0%)

Hypertension

11 (18.3%)

2 (3.3%)a

0 (0%)

0 (0%)

Bleeding

7 (11.7%)

1 (1.7%)b

2 (1.4%)

0 (0%)

Interstitial lung disease

1 (1.7%)

1 (1.7%)c

0 (0%)

0 (0%)

  1. aOne patient received Ramucirumab and it was switched to Bevacizumab due to severe hypertension
  2. bThe patient received Bevacizumab but it was discontinued due to severe nasal bleeding
  3. cThe patient received Afatinib but it was discontinued due to progressive interstitial lung disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us